Media headlines about STAAR Surgical (NASDAQ:STAA) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. STAAR Surgical earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 46.7471753203673 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- STAAR Surgical to Report Fourth Quarter Results… (benzinga.com)
- STAAR Surgical to Report Fourth Quarter Results on February 28, 2018 (finance.yahoo.com)
- STAAR Surgical (STAA) Expected to Post Earnings of $0.03 Per Share (americanbankingnews.com)
- Ocular Implants Market Analysis 2018 Globally: by Key Manufacturers, Countries, Type, Application and Forecasts to 2023 (medgadget.com)
Shares of STAAR Surgical (NASDAQ:STAA) traded down $0.10 during midday trading on Friday, reaching $15.10. 96,400 shares of the company traded hands, compared to its average volume of 109,861. STAAR Surgical has a twelve month low of $8.95 and a twelve month high of $17.60. The company has a market cap of $625.70, a PE ratio of -377.50 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.72 and a current ratio of 2.24.
In related news, VP Keith Holliday sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $16.65, for a total value of $99,900.00. Following the transaction, the vice president now owns 45,969 shares of the company’s stock, valued at approximately $765,383.85. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.60% of the stock is currently owned by company insiders.
WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2018/02/16/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-staar-surgical-staa-share-price.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.